Wednesday, 16th December
Eradicate Cancer 2020
Days
Tuesday, 15th December
Wednesday, 16th December
Search
Speakers
SESSION V: NK, CAR-NK, T, CAR- T CELLS
8:00AM - 10:05AM
Wednesday, 16th December
Chair: Alan Trounson
Adoptive T Cell Therapy: Of mice and men and memory
-
Cassian Yee
Perspectives on Immunotherapy with NK Cell Lines
-
Armand Keating
Developing a universal source for safe and off-the-shelf available therapeutical cells
-
Andras Nagy
OFF-THE-SHELF, GENE-EDITED iPSC DERIVED iNK CELLS
-
Nick Boyd
The cancer–natural killer cell immunity cycle
-
Nicholas Huntington
SESSION VI: IMMUNE RECONSTITUTION
8:00AM - 10:40AM
Wednesday, 16th December
Chair: Richard Boyd
Is there a role of the thymus in immunotherapy?
-
Georg Holländer
UM171-expanded cord blood transplants support robust T-cell reconstitution with low rates of severe infections
-
Maude Dumont-Lagacé
DL4-mbeads Induce T Cell Differentiation from Stem Cells in a Stromal Cell-Free System
-
JC Zuniga-Pflucker
Engineering Stem Cells for T cell Immunotherapy
-
Gay Crooks
Apoptosis, innate signalling, and repair: Exploiting endogenous thymic regeneration to boost immune function
-
Jarrod Dudakov
Modelling T-cell development using pluripotent stem cells
-
Ed Stanley
Development of “TCR cassette method”: a new method to transduce pluripotent stem cells with exogenous TCR gene
-
Hiroshi Kawamoto
Expanding the role of banked cord blood for non-homologous use.
-
Ngaire Elwood
SESSION VII: NK, NK-T CELLS
11:00AM - 12:45PM
Wednesday, 16th December
Chair: Fernando Guimaraes
Natural killer cell function in Multiple Myeloma patients in response to immunomodulatory therapy
-
Criselle DSouza
Therapeutic blockade of TGF-β superfamily members improves NK cell function and anti-tumor immunity
-
Fernando Guimaraes
Unconventional T cells offer new approaches for immunotherapy
-
Dale Godfrey
Butyrophilin 2A1 mediates phosphoantigen recognition and tumor targeting by gamma-delta T cells
-
Andreas Behren
and
Adam Uldrich
In depth characterization of CD8
+
T cells in a rare case of metastatic mucosal melanoma
-
Angela Pizzolla
Unlocking the potential of T cell therapies for solid tumors with genome editing
-
Jae Young Lee
SESSION VIII: NEW FRONTIERS
11:00AM - 12:40PM
Wednesday, 16th December
Chair: Deborah White
Tuning the drivers of Potency and Persistence in the Tumor Microenvironment
-
David Ferrick
DNA barcoding demonstrates immuno-editing of metastatic and non-metastatic breast cancer cells at the clonal level
-
Simon Junankar
Leukaemia genomics in the era of targeted and immunotherapies.
-
Deborah White
Targeting the gut microbiota to improve the safety and efficacy of agonistic cancer immunotherapies
-
Stephen J Blake
Advanced CAR-T Cell Tracking Technology
-
Ritu Singla
Capturing the cellular gymnastics of survival and killer proteins in B cell malignancies by mass cytometry
-
Charis Teh
LEARNING AT LUNCH
1:00PM - 1:15PM
Wednesday, 16th December
Immunometabolic application for developing effective cancer therapy
-
Sanket Joshi
SESSION IX: THE POWER OF INDUSTRY AND PHILANTHROPY - TRANSLATING PROMISING RESEARCH INTO CLINICAL THERAPIES
1:30PM - 3:30PM
Wednesday, 16th December
Chair: Ian Nisbet
Manufacturing of cellular therapies for clinical delivery: Transition from research to GMP
-
Dominic Wall
Philanthropy making hope real for blood cancer patients
-
Kirstee Macbeth
Cure Cancer: The Importance of Funding Early-Career Cancer Researchers
-
Nikki Kinloch
The power of the pivot - lessons for the development of breakthrough products
-
Ian Nisbet
SESSION X: OVERCOMING THE TUMOUR MICROENVIRONMENT AND CHALLENGES INHERENT TO SOLID CANCERS
1:30PM - 3:30PM
Wednesday, 16th December
Chair: Anne Fletcher
Interferon Epsilon – a new weapon in innate immunity against ovarian cancer
-
Paul Hertzog
Clinical performance of Immunoscore® in early colon cancer in the Asian population.
-
Marjane Le Bagousse
Conquering Immunosuppression in Localised Prostate Cancer using Radiation-Induced Immune Trafficking and Activation.
-
Simon P Keam
Co-targeting HCK in macrophages to improve anti-tumour responses to immunotherapy
-
Ashleigh Poh
Human T cell suppression triggered through cross-talk with cancer-associated fibroblasts
-
Anne Fletcher
IL-33 signalling and mast cells as new therapeutic targets against gastric cancer
-
Moritz Eissmann
Increased and co-localized CD4
+
FOXP3
+
and CD8
+
T cells is a strong independent prognostic indicator in gastric cancer
-
Minyu Wang
A tumour-specific survival switch in regulatory T cells
-
Daniel H.D. Gray
THANK YOU & CONFERENCE CLOSE
3:35PM - 3:45PM
Wednesday, 16th December
← Tuesday